Introduction {#s1}
============

Childhood-onset schizophrenia (COS) is a rare (\< 1/40,000) and severe chronic psychiatric condition that shares with adult-onset schizophrenia (AOS) positive symptoms (delusions, hallucinations, and disorganized speech or behavior), but presents an early onset (before the age of 13) ([@B16]; [@B49]). It remains considered by many authors as an early and severe variant of AOS ([@B49]; [@B14]). In COS, neurodevelopmental abnormalities (deficits in cognition, communication, or neuromotor impairments) and premorbid dysfunction are more frequent compared with AOS ([@B78]) and a clinical overlap exists with other neurodevelopmental disorders: 28% of patients with COS in the US cohort of the National Institute of Mental Health Child Psychiatry Branch met criteria for comorbid autism spectrum disorder (ASD) ([@B55]). In addition, more than 80% of children with schizophrenia or schizoaffective disorder present comorbid attention deficit and hyperactivity disorder (ADHD) ([@B61]). Few genetic studies of COS were reported, due to the very low prevalence (\<1/40,000) ([@B16]) and to nosographic difficulties, which made it hard to obtain a consensual clinical definition of this disorder and to carry out etiological studies ([@B46]; [@B30]). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) classification provides recent clarification in this area with schizophrenia no longer excluding the diagnosis of ASD ([@B54]; [@B10]). Thus, clinical overlap between COS and ASD is now formally accepted. Surprisingly, DSM-5 still does not recognize the existence of COS, which therefore remains considered an adult clinical presentation (AOS) ([@B10]). Indeed, COS is a very rare complex disorder related to other neurodevelopmental disorders, and it represents a real challenge for clinical diagnosis with, to date, no objective test based on genetics ([@B54]). However, a high heritability rate of COS (\> 80%) has been suggested in early adoption/twin studies ([@B40]) and has been confirmed by familial aggregation studies ([@B12]). To determine the etiology of COS, it is indispensable to start by reviewing the publications that have linked COS to DNA changes.

Macro-lesional cytogenetic abnormalities such as copy number variations (CNVs), including the 22q11.21 deletion, are more frequent in COS than in AOS \[10.6% of patients with COS (DSM-III-R, onset \<13 years) vs. 2--5%, in AOS, p \< 0.0001\]. These anomalies in the general population would concern only 0.86% of newborns ([@B50]).

Recently, Next Generation Sequencing (NGS) or "high throughput sequencing" allowed, with unprecedented scalability and speed, to determine the DNA sequence of a given individual. This tool opened up new perspectives to understand complex neurodevelopmental disorders, with particular attention to *de novo* single nucleotide variations (SNVs) occurring in genes involved in brain development ([@B77]). Only one study used whole exome sequencing (WES), a NGS method, in a cohort of patients with COS. This study identified 20 *de novo* variants in 17 COS probands (rate: 1.17) in genes previously linked to neuronal function or to psychiatric disorders ([@B8]). These arguments (phenotypic overlap with other neurodevelopmental disorders, high heritability, disease-related CNVs, and *de novo* SNV rates) strongly support the neurodevelopmental and genetic bases of COS ([@B57]). In this context, the main aim of this study is to describe the COS genomic variation (CNVs and SNVs) in the scientific literature to identify interesting genes or genetic pathways in both clinical practice and research.

Methods {#s2}
=======

We carried out a systematic review of the MEDLINE database accessible *via* the search engine PubMed ([www.ncbi.nlm.nih.gov/pubmed/](www.ncbi.nlm.nih.gov/pubmed/)) with the following key words: "childhood-onset schizophrenia" or "childhood-onset psychosis" or "early-onset schizophrenia" or "early-onset psychosis" and "genetics" or "genetic" or "gene" or "genes" or "genomic" or "genomics." Our search terms were not limited by language or date of publication and were manually reviewed. According to inclusion criteria, we considered all genomic changes occurring in COS patients (age of onset before 13). We excluded all abnormalities at RNA or protein levels (regardless the age of onset). Genomic variations were classified based on cytogenetic position ([**Table 1**](#T1){ref-type="table"}) and candidate gene names ([**Table 2**](#T2){ref-type="table"}).

###### 

Cytogenetic abnormalities (including copy number variations) in COS patients with their localization, length and type of inheritance.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  CHR     CNV region and type (length)                Sex, age of onset   Neurodevelopmental disorders, Comorbidities                                                                                      Inheritance                                                 coordinates (hg18-*hg19*)                                                 SFARI   Clinical significance   Bibliography
  ------- ------------------------------------------- ------------------- -------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------- ------- ----------------------- -----------------------------------------------------------------
  1       DUP 1q21.3\                                 Male, 12 y          −                                                                                                                                inherited                                                   chr1:151,514,380-151,762,871                                              \+      UCS                     [@B79]
          (248 kb)                                                                                                                                                                                                                                                                                                                                                               

  1 ; 7   t(1;7) (p22;q22)                            Male, 9 y           ASD? - ADHD? - language, intellectual and motor impairments, dysmorphia, supraventricular tachycardia                            inherited (father)                                          −                                                                         −       −                       [@B32]; [@B50]; [@B83]; [@B38]; [@B26]; [@B1]\*

  2       DUP 2p14 (243 kb)                           \<13 y              −                                                                                                                                inherited                                                   chr2:65,637,097-65,879,935                                                \+      UCS                     [@B79]

          DEL 2p16.3 (115 \--\> 112 kb) NRXN1         \<13 y              −                                                                                                                                not known                                                   chr2:50,023,212-50,137,825 / chr2:50,025,162-50,136,989                   \+      P                       [@B79]; [@B1]\*, [@B6]

          DEL 2p16.3 (38 et 40kb) NRXN1               Male, 12 y          Motoric and verbal delay, IQ 82, macrocencephalia and increase height (+3SD)                                                     inherited (father)                                          chr2:51,151,955-51,190,352 / chr2:51,440,969-51,481,281                   \+                              [@B25]

          DUP 2p25.3 (216 \--\> 245 kb) MYT1L         \<13 y              −                                                                                                                                inherited (mother)                                          chr2:1,618,945-1,835,426 / chr2:1,591,064-1,836,375                       \+      P                       [@B79]; [@B1]\*, [@B6]; [@B43]

          DUP 2p25.3 (143 \--\> 107kb ) MYT1L         \<13 y              −                                                                                                                                not known                                                   chr2:1,713,636-1,857,129 / chr2:1,720,133-1,827,317                                                       

          DEL 2q31.2-31.3 (2,5 Mb)                    Male, 11 y          −                                                                                                                                de novo or germline mosaicism in one of the parents         chr2:179,643,864-182,145,339                                              \-      UCS                     [@B79]; [@B1]\*

  3       DEL 3p12.2-p12.1 (2,2 Mb)                   Female, 12 y        ASD, poor motor coordination, IQ 67                                                                                              inherited (father)                                          −                                                                         \-      UCS                     [@B62]

          DUP 3p21.31 (117 Kb)                        \<13 y              −                                                                                                                                inherited                                                   chr3:45,458,901-45,576,135                                                \+      UCS                     [@B79]

          DUP 3p25.3 (120 \--\> 134 kb) SRGAP3        Male, 11 y          poor peer relationships, general anxiety disorder, panic disorder, agoraphobia, and depression                                   inherited (father)                                          chr3:9,100,744-9,220,529 / *chr3: 9,111,177--9,245,155*                   \+      P                       [@B79]; [@B1]\*, [@B80]

          DEL 3q29 (1,58 Mb)                          Male, 5 y           ASD, severe abdnormal movements and tics                                                                                         de novo                                                     chr3:197,161,073-198,851,029                                              \+      P                       [@B64]

  5       DUP 5q12.3 (142 Kb)                         Female, 10 y        −                                                                                                                                inherited                                                   chr5:64,795,287-64,937,409                                                \+      UCS                     [@B79]

          Paternal segmental iUPD 5q32-qter (35 Mb)   Female, 9 y         MDD, inattention,learning disability, intellectual impairments                                                                   *de novo*                                                   −                                                                         −       −                       [@B26]; [@B1]\*, [@B66]

  6       DEL 6p22.31 (144 kb)                        Male, 9 y           OCD, expessive language disorder                                                                                                 inherited                                                   chr6:119,596,633-119,740,850                                              \+      UCS                     [@B79]

  7       DUP 7p13 (120 Kb)                           \<13 y              −                                                                                                                                not known                                                   chr7:44,420,900-44,540,491                                                \-      UCS                     [@B79]

          DUP 7q11.21-q11.22 (2,8 Mb)                 \<13 y              −                                                                                                                                inherited                                                   chr7:64,126,564-66,883,376                                                \+      UCS                     

  8       DUP 8p22 (1,3 Mb)                           Male, 11 y          −                                                                                                                                inherited                                                   chr8:13,400,795-14,679,483                                                \+      UCS                     [@B79]

          DUP 8q11.23 (480 kb \--\> 493 kb)           \<13 y              −                                                                                                                                not known                                                   chr8:53,563,161-54,043,063 / chr8:53,550,992-54,043,684                   \+      UCS                     [@B79]; [@B6]

          DUP 8q24.3 (369 Kb) PTK2                    12 y                −                                                                                                                                not known                                                   chr8:142,025,432-142,393,948                                              \+      UCS                     [@B79]

  9       DEL 9p24.2 (440 Kb)                         11 y                −                                                                                                                                −                                                           chr9:3,104,250-3,544,339                                                  \+      UCS                     

  10      DUP 10p11.23 (176 Kb)                       Male, 11 y          −                                                                                                                                inherited                                                   chr10:28,990,284-29,166,175                                               \+      UCS                     [@B79]

          DUP 10p13 (145 Kb)                          \<13 y              −                                                                                                                                inherited                                                   chr10:15,688,654-15,833,865                                               \+      UCS                     

          DEL 10q22.3 (173 kb)                        Male, 12 y          −                                                                                                                                *de novo*                                                   chr10:81,415,378-81,588,866                                               \+      UCS                     [@B6]

          DEL 15q11.2 (1386 kb)                       \<13 y              −                                                                                                                                not known                                                   chr15:18,818,086-20,203,694                                               \+      UCS                     [@B6]

  15      DEL 15q11.2 (575kb)                         \<13 y              −                                                                                                                                inherited (mother)                                          chr15:20,203,​694-20,778,963                                                                              

          DEL 15q13.3 (382kb)                         \<13 y              −                                                                                                                                *de novo*                                                   chr15:30,238,780-30,620,951                                               \+      P                       

          DEL 15q13.3 (475 kb)                        \<13 y              −                                                                                                                                inherited (mother)                                          chr15:30,238,780-30,713,368                                                                               

          DUP 15q13.3 (503.5 Kb) CHRNA7               Female, 10 y        −                                                                                                                                inherited (father)                                          chr15:32,012,361-32,515,849                                               \+                              [@B85]

          DUP 15q13.3 (600,2 Kb) CHRNA7               Male, 12 y          ADHD                                                                                                                             chr15:32,019,919--32,620,127                                                                                                                                          

          DUP 15q26.2-q26.3 (687 Kb)                  \<13 y              −                                                                                                                                not known                                                   chr15:96,246,764-96,933,404                                               \+      UCS                     [@B79]

  16      DUP 16p11.2\                                8 y                 PDD-NOS, poor social and motor development                                                                                       inherited (father)                                          chr16:29,652,656-30,085,308 / chr16:29,502,984-30,107,306                 \+      P                       [@B79]; [@B1]\*, [@B6]; [@B56]
          ( 433 \--\> 604 Kb)                                                                                                                                                                                                                                                                                                                                                    

          DUP 16p11.2\                                10 y                Poor social and motor development                                                                                                chr16:29,657,405-30,235,818 / chr16:29,782,436-30,227,808                                                                                                             
          ( 578 \--\> 445 kb)                                                                                                                                                                                                                                                                                                                                                    

          DEL 16p12.1 (449kb)                         −                   −                                                                                                                                father                                                      chr16:21,498,074-21,946,841                                               \+      UCS                     [@B6]

          DEL 16p13.11\                               Male, 6 y           Motor dyscoordination, langage impairments                                                                                       Father or de novo                                           *chr16:1,51,32,264--1,51,47,411 (min) to 1,50,48,733-1,51,79,946 (max)*   *+*     UCS                     [@B15]
          (15 à 131 kb)                                                                                                                                                                                                                                                                                                                                                          

          DUP 16p13.11 (1,4 à 1,7 Mb)                 Female, 4 y         ASD, Epilepsy, Chiari 1                                                                                                          father                                                      *chr16:1,48,97,761--1,62,76,117 to 1,47,80,303--1,64,58,270*                      UCS                     

          DUP 16q22.2-ter (17 Mb)                     Female, 11 y        Atypical Turner, motor, language and attention impairments                                                                       −                                                           −                                                                         −       P                       [@B26]

          DUP 16q22.3-q24.3 (16,7 Mb)                 Female, 12 y        ASD, poor motor coordination, IQ 67                                                                                              *de novo*                                                   −                                                                         −       P                       [@B62]

          DUP 16q23.3\                                Female, 9.5 y       −                                                                                                                                inherited                                                   chr16:80,737,839-82,208,451                                               \+      UCS                     [@B79]
          (1,5 Mb)                                                                                                                                                                                                                                                                                                                                                               

          DEL 16q24.1\                                \<3 y               −                                                                                                                                inherited                                                   chr16:82,997,582-83,108,554                                               \+      UCS                     
          (111 Kb)                                                                                                                                                                                                                                                                                                                                                               

  17      DUP 17q21.31 (384 kb)                       \<13 y              −                                                                                                                                father                                                      chr17:41,321,621-41,706,070                                               \+      UCS                     [@B6]

  18      DUP 18p11.31-p11.23 (510 kb)                \<13 y              −                                                                                                                                inherited                                                   chr18:7,067,237-7,576,777                                                 \+      UCS                     [@B79]

          DUP 18q22.1 (768 Kb)                        Male, 10 y          Asperger\'s disorder                                                                                                             inherited                                                   chr18:61,907,915-62,675,869                                               \+      UCS                     [@B79]

  19      DEL 19p12\                                  \<13 y              −                                                                                                                                not known                                                   chr19:23,413,380-23,810,606                                               \+      UCS                     [@B79]
          (397 Kb)                                                                                                                                                                                                                                                                                                                                                               

  20      DEL 20p12.1\                                10 y                Poor social and motor development                                                                                                inherited                                                   chr20:14,921,777-15,034,862                                               \+      UCS                     [@B79]
          (113 Kb)                                                                                                                                                                                                                                                                                                                                                               

  22      DEL 22q11.2 (3Mb) PRODH DGCR6               Male, 9 y           Language, motor and social impairments, generalized anxiety disorder, dysthymia and ADHD, craniofacial dysmorphia, hypospadias   de novo                                                     −                                                                         \+      P                       [@B50]; [@B26]; [@B1]\*, [@B55]; [@B82]; [@B75]; [@B44]; [@B71]

                                                      Female, 12 y        Language, motor and social impairments, craniofacial dysmorphia, celiac disease and ureteric reflux                              de novo                                                     −                                                                                                         [@B50]; [@B26]; [@B1]\*, [@B56]; [@B75]; [@B44]; [@B71]

                                                      Female, 10 y        Language, motor and social impairments, craniofacial dysmorphia                                                                  de novo                                                     −                                                                                                         

                                                      \<13 y              Craniofacial dysmorphia                                                                                                          −                                                           −                                                                                                         [@B26]; [@B1]\*, [@B55]; [@B71]

          DEL 22q11.21 (3 Mb)                         \<13 y              −                                                                                                                                *de novo*                                                   chr22:17,092,563-20,077,678                                               \+                              [@B6]

          DEL 22q11.21 (2,6 Mb)                       \<13 y              −                                                                                                                                *de novo*                                                   chr22:17,224,632-19,842,333                                                                               

          DEL 22q11.21 (2,6 Mb)                       \<13 y              −                                                                                                                                not known                                                   chr22:17,257,787-19,855,248                                                                               

          DEL 22q11.21 (2,7 Mb)                       \<13 y              −                                                                                                                                *de novo*                                                   chr22:17,257,787-19,963,350                                                                               

          DEL 22q11.21 (2,9 Mb)                       \<13 y              −                                                                                                                                *de novo*                                                   chr22:17,269,794-20,128,199                                                                               

          DUP 22q13.32 (1,6 Mb)                       8 y                 PDD-NOS, poor social and motor development                                                                                       *de novo*                                                   chr22:47,903,228-49,557,485                                               \+      UCS                     [@B6]

  X       expansion CGG (1,5 Kb) FMR1                 Female, 9 y         Dysmorphia, learning and social impairments, mild MR                                                                             mother                                                      −                                                                         −       −                       [@B76]

          47, XXX                                     Female, \<13 y      −                                                                                                                                −                                                           −                                                                         −       −                       [@B26]; [@B1]\*

          46,X,i(X)(q10)(22%)/45,X(78%)               Female, \<13 y      Mosaic Turner                                                                                                                    *de novo*                                                   −                                                                         −       −                       

          DEL Xq24-qter                               Female, 11 y        Atypical Turner, motor, language and attention impairments                                                                       *de novo*                                                   −                                                                         \-      P                       [@B50]; [@B26]; [@B1]\*, [@B42]

          DUP Xp22.31 (342 Kb)                        \<13 y              −                                                                                                                                not known                                                   chrX:8,384,117-8,726,291                                                  \+      UCS                     [@B79]

          DEL Xp22.31 (1.68 Mb) STS                   Male, 11 y          Congenital ichthyosis, microcencephalia, epilepsy. Language, motor, social, learning impairment, IQ 57, ADHD, ASD                                                                            *chrX:6,456,036-8,139,238*                                                        UCS                     [@B47]

          DUP Xq28\                                   Female, 4 y         ASD, Epilepsy, Chiari 1                                                                                                          *de novo*                                                   *chrX:15,29,55,334--15,29,61,664 to* *15,29,51,719--15,29,86,547*         *+*     UCS                     [@B15]
          (6 a 35 Kb)                                                                                                                                                                                                                                                                                                                                                            

          DEL Xq23-q28 (43 Mb)                        Female, 12 y        ASD, poor motor coordination, IQ 67                                                                                              *de novo*                                                   −                                                                         \+      P                       [@B62]

  Y       DUP Yq11.221 (183 Kb)                       Male, 8 y           Generalized anxiety disorder                                                                                                     *de novo*                                                   chrY:14,441,161-14,623,937                                                \+      UCS                     [@B79]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADHD, Attention Deficit Hyperactivity Disorder; ASD, Autism Spectrum Disorder; CNV, Copy number variation; COPD, Chronic Obstructive Pulmonary Disease; DEL, Deletion; DUP, Duplication; iUPD, Uniparental isodisomy; ID, Intellectual disability; Kb, Kilobases; Mb, Mégabases; MDD, Major Depressive Disorder; MR, Mental Retardation; OCD, Obsessive compulsive disorder; P, Pathogenic; PDD-NOS, Pervasive developmental disorder not otherwise specified; UCS, Uncertain Clinical Significance; VCF, Velocardiofacial; Y, Years; \* Literature review.

When available, phenotypes (sex, age of onset, other neurodevelopmental disorders and comorbidities) are described.

###### 

Genomic microlesions (including single nucleotide variations) in COS patients with their localization, length, and type of inheritance.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene name                                              Gene localization   SNV ID number/mutation (protein level)   Population / Phenotypes                                                                    Inheritance   p-value         Bibliography
  ------------------------------------------------------ ------------------- ---------------------------------------- ------------------------------------------------------------------------------------------ ------------- --------------- --------------
  **FAMILY BASED ASSOCIATION STUDY**                                                                                                                                                                                                           

  **DAOA (G72) / DAOA-AS1 (G30)**                        13q33.2             rs1935058, rs3916967, rs2391191          n=64 (53 COS trios, 11 COS dyads)                                                          −             0.015 to 0.5    [@B2]

  **DTNBP1**                                             6p22.3              rs11558324                               n=92 (73 COS + PDD-NOS trios, 19 COS + PDD-NOS dyads)                                      −             0.014           [@B33]

  **GAD1**                                               2q31.1              rs3749034, rs2270335, rs2241165          n=66 (55 COS + PDD-NOS trios, 11 COS + PDD-NOS dyads)                                      −             0.005           [@B3]

  **NRG1**                                               8p12                rs35753505, rs2881272, rs327417          n=70 (59 COS + PDD-NOS trios, 11 COS + PDD-NOS dyads)                                      −             0.009 to 0.05   [@B4]

  **CASE CONTROL STUDY**                                                                                                                                                                                                                       

  **BDNF**                                               11p13               val66met                                 65 patients (10.5 ± 3.7 y) vs\                                                             −             0.03            [@B51]
                                                                                                                      111 controls                                                                                                             

  **COMT**                                               22q11.21            val158met                                83 patients (\<13 y) vs\                                                                   −             −               [@B58]
                                                                                                                      208 controls                                                                                                             

  **TPH1**                                               11p15.3-p14         ala218cys                                51 patients (\<16 y) vs\                                                                   −             0.0058          [@B67]
                                                                                                                      148 controls                                                                                                             

  **GENES SEQUENCING (candidate genes or full exome)**                                                                                                                                                                                         

  **ATP1A3**                                             19q13.2             val129met                                Male, onset: 6 y, motor delay                                                              *de novo*     −               [@B68]

                                                                             asp801asn                                Male, onset: 10 y, ASD, dysmophia, motor, intellectual and learning delays. Recurent MDD                 −               [@B21]

                                                                             glu815lys                                Male, onset: 12 y, motor and communication impairments, dysmophia, ASD                                   −               

                                                                             ala813val                                Male, onset: 10 y, ASD, motor and intellectual delays                                      mother        −               

  **FXYD1**                                              19q13.12            arg90cys                                 Male, onset: 7 y, Asperger\'s disorder                                                     inherited     −               

  **FXYD6-FXYD2**                                        11q23.3             val101ala                                Male, onset: 13 y                                                                                        −               

  **FXYD6**                                              11q23.3             gly73arg                                 Female, onset: 12 y                                                                                      −               

  **GPR153**                                             1p36.31             arg73cys                                 Male, onset: 12 y                                                                          *de novo*     −               [@B8]

  **GTF2IRD1**                                           7q11.23             arg357cys                                Female, onset: 12 y                                                                                      −               

  **ITGA6**                                              2q31.1              glu1063del                               Female, onset: 12 y                                                                                      −               

  **LUZP4**                                              Xq23                arg278fs\*10                             −                                                                                          mother        −               [@B9]

  **OPHN1**                                              Xq12                met461val                                IQ 88, PDDNOS                                                                                            −               

  **PCDH19**                                             Xq22.1              leu1022ile                               −                                                                                                        −               

  **RPS6KA3**                                            Xp22.12             arg723his                                IQ 64, PDDNOS                                                                                            −               

  **RYR2**                                               1q43                glu746tyr                                Male, onset: 8 y, PDDNOS, separation anxiety disorder, Asperger\'s disorder                *de novo*     −               [@B8]

  **SEZ6**                                               17q11.2             thr229_thr231del                         Male, onset: 11 y                                                                                        −               

  **TTBK1**                                              6p21.1              arg258gln                                Male, onset: 7 y, Asperger\'s disorder                                                                   −               

  **UPF3B**                                              Xq24                gln228fsX18                              Male, 10 y, ADHD, PDDNOS, ASD                                                              mother        −               [@B5]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADHD, Attention Deficit Hyperactivity Disorder; ASD, Autism Spectrum Disorder; CNV, Copy number variation; COS, Childhood Onset Schizophrenia; DEL, Deletion; DUP, Duplication; MDD, Major Depressive Disorder; PDD-NOS, Pervasive developmental disorder not otherwise specified; SNV, Single Nucleotide Variation; Y, Years. When available, phenotypes (sex, age of onset, other neurodevelopmental disorders, and comorbidities) are described.

All CNVs were manually annotated using the University of California Santa Cruz (UCSC) Genome Browser (UCSC Mar. 2006 (NCBI36/hg18 or NCBI37/hg19) assembly; <http://genome.ucsc.edu/>). Regarding their type (gain or loss), their size, their genomic content, and making comparisons with external databases, we ranked each CNV as "pathogenic," "uncertain clinical significance," or "benign" (according to the American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants). For each CNV, we checked on the Simons Foundation Autism Research Initiative (SFARI) Gene database (autism/genetic database, <http://sfari.org>) which CNV involved in COS was also involved in ASD. For each gene, we checked on the Phenocarta Database (<https://gemma.msl.ubc.ca/home.html>) the evidence linking genes to phenotypes of neurodevelopmental disorders ([**Figure 1**](#f1){ref-type="fig"}, Venn diagram). Phenotypes were systematically described, if available.

![Venn diagram: evidence for genetic overlap in neurodevelopmental disorders (Phenocarta Database).](fgene-10-01137-g001){#f1}

The selection took place before September 2018. At this time, 36 articles (1994 to 2018) out of 205 (1982 to 2018) met the inclusion criteria. Article reviewing process, including selection and exclusion, is summarized in a PRISMA flow diagram ([**Figure 2**](#f2){ref-type="fig"}). Two articles were added after the freezing of the inclusion process (41; 52). Mutations were identified in 21 chromosomes. The results were ranked either in ascending order of their chromosomal position for structural variants (cytogenetic abnormalities) ([**Table 1**](#T1){ref-type="table"}) or in alphabetical order according to their gene name for genetic variants (lesions at gene level) ([**Table 2**](#T2){ref-type="table"}).

![PRISMA Flowchart diagram.](fgene-10-01137-g002){#f2}

Results {#s3}
=======

I. Cytogenetic Abnormalities Associated With COS {#s3_1}
------------------------------------------------

The following cytogenetic abnormalities (n = 72, including 66 CNVs) were identified in 16 autosomes (1, 2, 3, 5, 6, 7, 8, 9, 10, 15, 16, 17, 18, 19, 20, and 22) and two sex chromosomes (X and Y) of 46 patients (17--40). The results were ranked in ascending order of their chromosomal position ([**Table 1**](#T1){ref-type="table"}) and were summarized in a genomic map ([**Figure 3**](#f3){ref-type="fig"}).

1.  1\) CNVs

    a.  Deletions (CNVs) from 15Kb to 43Mb: 2p16.3, 2q31.2-q31.3, 3p12.2-p12.1, 3q29, 6p22.31, 9p24.2, 10q22.3, 15q11.2, 15q13.3, 16p12.1, 16p13.11, 16q24.1, 19p12, 20p12.1, 22q11.21, Xp22.31, Xq24-ter, and Xq23-q28;

    b.  Duplications (CNVs) from 120Kb to 17Mb: 1q21.3, 2p14, 2p25.3, 3p21.31, 3p25.3, 5q12.3, 7p13, 7q11.21-q11.22, 8p22, 8q11.23, 8q24.3, 10p11.23, 10p13, 15q11-q13, 15q13.3, 15q26.2--26.3, 16p11.2, 16p13.11, 16q22.2-ter, 16q22.3-q24.3, 16q23.3, 17q21.31, 18p11.31-p11.23, 18q22.1, 22q13.32, Xp22.31, Xq28, and Yq11.221.

![Genomic map of CNVs identified in COS. Circles indicate their position and color represents type of abnormality (Red circle, deletion; Blue circle, duplication).](fgene-10-01137-g003){#f3}

Only six CNVs (9%) of our study are described in COS only: del2q31.2-q31.3 (smaller than the CNV described in ASD), del3p12.2-p12.1 (described in ASD as a duplication), delXq24-ter (larger than the CNV described in ASD), dup7p13 (described in ASD as a deletion), dup16q22.2-ter (larger than the CNV described in ASD), and dup16q22.3-q24.3 (larger than the CNV described in ASD).

In an on-site case series and literature review focusing on Childhood-Onset Schizophrenia Spectrum Disorders (SSDs; larger spectrum than COS), Giannitelli et al. (2018) showed that some CNVs, previously un-described in COS patients, are associated to childhood psychosis: 1q21.1 deletion, 1q21.1 duplication, Williams-Beuren region (7q11.23) duplication and 16p11.2 deletion ([@B28]).

The phenotypes of only 15 out of the 46 patients were fully described (33%). The neurodevelopmental disorders that have been presented are: motor impairments (fine or growth milestones delay, coordination disability, or tics) in 11/15 patients, language retardation in 7/15 patients, intellectual disability (IQ \< 70) in two patients, and ASD in five patients \[(including 1 Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS)\]. Social impairment was present in six other patients with COS and ADHD in three patients. Inattention impairment was specified in only one patient. The psychiatric comorbidities that have been highlighted are: two cases with mood disorders (major depressive disorder or dysthymia) and two cases with anxiety disorders. The somatic comorbidities detected are: dysmorphia in four cases and epilepsy in two cases. Sporadic cases of hypospadias, ureteric reflux, congenital ichthyosis, Chiari type 1, or celiac disease were also described.

1.  2\) Other DNA Lesions

    a.  Aneuploidy

        One case of Trisomy X (47XXX) and two cases of Turner syndrome (45X0), one atypical form (46,X,del(X)(q24-ter) and one with mosaicism 46,X,i(X)(q10)(22%)/45,X(78%) ([@B26]; [@B1]);

    b.  Uniparental and Segmental isoDisomy (iUSD)

        In isodisomy, both copies of a chromosomal set are inherited from one parent (the mother or the father). An iUSD on 5q32-ter (35Mb) was described in a patient with COS ([@B26]; [@B1]; [@B66]);

    c.  Translocation 1, 7: p22q22 ([@B32]; [@B50]; [@B83]; [@B26]; [@B38]; [@B1])

    d.  Trinucleotide Repeat Expansions

        i.  CGG Expansions: Although a link between Fragile X syndrome (FXS) and COS has never been reported, [@B76] described a 1.5 Kb expansion and complete methylation of the CpG island upstream of FMR1 in a 9 years-old girl with COS, dysmorphia, learning and social impairments, and mild mental retardation ([@B76]). This abnormality is inherited from the mother who carries an FXS premutation. Interestingly, instead of being unaffected or weakly affected as most patients carrying a premutation, the mother presents schizotypal personality. It seems that the severity of the schizophrenic spectrum disorder, which affects both mother and daughter with gradual severity, is linked to the CGG expansion degree. Effect of the hazard could not be excluded in this case ([@B76]).

        ii. CAG/CTG Expansion: a longer repeat expansion on chromosome 18 was found in a COS cohort and in a male subclass, with a significant p-value especially for the males (0.036 and 0.002, respectively; Wilcoxon--Mann--Whitney U test) ([@B17]).

    e.  Genetic Syndromes

        In their recent review, [@B28] showed that some genetic syndromes, previously un-described in COS, are associated to childhood-onset SSDs: juvenile Huntington disease, Prader-Willi syndrome, Steinert myotonia, Ondine syndrome, Rubinstein-Taybi syndrome, and GLUT1 deficiency syndrome ([@B28]).

II. Genes Associated With COS {#s3_2}
-----------------------------

In total, 32 candidate genes have been described on 12 autosomes (1, 2, 3, 6, 7, 8, 11, 13, 15, 17, 19, and 22) and 1 sex chromosome (X) ([**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}) through the following studies ([@B2]; [@B67]; [@B33]; [@B3]; [@B4]; [@B51]; [@B5]; [@B58]; [@B68]; [@B21]; [@B9]):

1.  1\) Genetic Association Studies ([**Table 2**](#T2){ref-type="table"})

    a.  Family-Based "Transmission Disequilibrium Test" Studies (From 2004 to 2007)

        Transmission disequilibrium test, a family-based association test for the presence of genetic linkage between a genetic marker and a trait, was used to describe the following candidate genes: *DAOA, DAOA-AS1, DTNBP1, GAD1*, and *NRG1*. The Linkage Disequilibrium Analyses for Quantitative and Discrete Traits (QTDT) program was used to make statistical analysis (p-values).

        i.  *DAOA* and *DAOA-AS1* ([@B2]): three Single Nucleotide Polymorphisms (SNPs) are associated with COS (rs1935058, rs3916967, and rs2391191 (p = 0.5, 0.015, 0.3, respectively)). The most significant SNP (p = 0.015) is rs3916967 (genomic sequence reference: NG_012694.1:g.4133T \> C);

        ii. *DTNBP1* ([@B33]): one SNP, rs11558324 (NG_009309.1:g.5154A \> G), is associated with COS (p = 0.014) and two two-marker haplotypes (containing rs11558324) are also associated with COS (p = 0.021, 0.008),

        iii. *GAD 1* ([@B3]): three four-marker haplotypes are associated with COS (p = 0.005);

        iv. *NRG1* ([@B4]): individual markers show association with COS (rs35753505, rs2881272, 420M9-1395 (microsatellite), and rs327417, with p-value between 0.009 and 0.05). The most significant SNP (p = 0.009) is rs327417 (NG_012005.2:g.341913G \> A). Further, several novel four-marker haplotypes are associated with COS (lowest p = 0.0004).

    b.  Population-Based "Case vs. Control" Studies (From 2004 to 2011)

        A polymorphism (VAL66MET) in the *BDNF* (11p13) gene was associated with COS in a 65 patient cohort (10.5 ± 3.7 years old at onset) vs. 111 controls (p = 0.03; χ² test) ([@B51]). A mutation (VAL158MET) in *COMT* (22q11.21) that increases protein activity levels in the brain accelerated adolescent cortical thinning (MRI findings) in both schizophrenia probands and their siblings (with resolution after a certain age for siblings), illustrating the influence of dopaminergic disruption on brain cortical maturation. Authors analyzed data from an 83 COS patient cohort vs. 208 healthy controls ([@B58]). A mutation (A218C) in the *TPH1* (11p15.3-p14) gene (p = 0.0058; χ² test) is described in 51 patients (early adolescent onset cohort before 16 years old) vs. 148 controls ([@B67]).

2.  2\) Gene Sequencing Studies (2011 to Present)

    Finally, five studies by DNA sequencing (candidate genes or whole exome sequencing) have allowed identifying the following 18 mutations in 11 genes ([@B5]; [@B8]; [@B68]; [@B21]; [@B9]).

```{=html}
<!-- -->
```
i.  Six SNVs inherited from a healthy mother:

    1.  \- Five X-linked recessive variants: *LUZP4* (arg278fs\*10), *OPHN1* (met461val), *PCDH19* (leu1022ile), *RPS6KA3* (arg723his), and *UPF3B* gene (gln228fsX18) that also segregates in the sibling.

    2.  \- One SNV (ala813val) in *ATP1A3* (a boy with onset at 10 years old and co-morbid ASD).

ii. Three SNVs inherited (missenses variants) in the FXYD gene family. *FXYD1* (arg90cys), *FXYD6-FXYD2* (val101ala), and *FXYD6* (gly73arg) genes. Only the patient with the mutation in FXYD1 presents a co-morbid ASD (Asperger's disorder).

iii. Nine *de novo* SNVs in the following genes: *ATP1A3* (val129met; asp801asn; glu815lys), *GPR153* (arg73cys), *GTF2IRD1* (arg357cys), *ITGA6* (glu1063del), *RYR2* (glu746tyr), *SEZ6* (thr229_thr231del), and *TTBK1* (arg258gln).

The ATPase Na^+^/K^+^ transporting Alpha-3 Polypeptide (*ATP1A3* gene) encodes the alpha-3 catalytic subunit of the Na^+^/K^+^-ATPase transmembrane ion pump mapping at 19q12-q13.2 ([@B34]). The *ATP1A3* isoform is exclusively expressed in neurons of various brain regions, including the basal ganglia, hippocampus, and cerebellum (summary by [@B60]). Mutations in this gene have been associated with a spectrum of disorders depending on the domain they affect in the corresponding protein. The majority of mutations associated with rapid-onset dystonia parkinsonism, or dystonia-12 (*DYT12*), were located in exons 8 and 14 whereas those with alternating hemiplegia of childhood-2 (AHC2) were located in exons 17 and 18 and in general they seem to affect transmembrane and functional domains, being the most severe dysfunctions. By genetic analysis of clinical data from 155 patients with AHC2, 132 confirmed to have *ATP1A3* mutations. Among those with AHC2, the most frequent mutations were D801N (in 43%), E815K (in 16%) and G947R (in 11%). E815K was associated with a severe phenotype, with greater intellectual and motor disability; D801N appeared to confer a milder phenotype and G947R correlated with the most favorable prognosis. For those with epilepsy, the age at seizure onset was earlier for patients with the E815K or G947R mutations than for those with the D801N mutation ([@B52]). In 10 patients from three unrelated families with cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS; 601338) ([@B24]), the same heterozygous missense mutation in the *ATP1A3* gene was identified (E818K; OMIM 182350.0014).

The G Protein-coupled Receptor 153 (*GPR153*) gene, located on 1p36.31, belongs to the large rhodopsin (RHO; OMIM 180380) family of GPCRs ([@B29]) and shows a highest similarity to serotonin receptors, ([@B29]). Furthermore, knockdown of *GPR153* in mice showed reduction in food intake and increased anxiety according to the elevated plus Maze test ([@B72]).

The InTeGrin Alpha-6 (*ITGA6*) gene is located on 2q31.1 ([@B36]). While functional absence of *ITGA6* has been associated with epidermolysis bullosa ([@B36]; [@B27]), a few works addressed the role of *ITGA6* in neurons. Alpha-6 integrin was initially reported to be involved in neural migration ([@B84]). In addition, recent data suggested that α6 and β1 integrins may play a role in mediating Schwann cell interactions with axons and promote axonal regeneration ([@B20]).

The RYanodine Receptor 2 (*RYR2*) gene---located on chromosome 1 between q42.1 et q43---encodes a calcium channel that is located in the sarcoplasmic reticulum and is the major source of calcium required for cardiac muscle excitation-contraction coupling. ([@B13]). Ryr2-/- mice die at approximately embryonic day 10 with morphologic abnormalities in the heart tube. Ca^2+^ signaling has been associated with ASD ([@B39]; [@B73]; [@B18]) and with other psychiatric and neurological diseases ([@B35]). It is not surprising that *RYR2* was linked to ASD by genetic studies ([@B45]; [@B70]; [@B22]). However, it is very interesting to underline that an SNP in this gene was associated with ASD in families with only affected males in contrast with those with affected females ([@B45]) suggesting that *RYR2* is a sex-related genetic factor for ASD.

The SEiZure-related 6 (*SEZ6*) gene is located on the 17q11.2 chromosome. Sez6 types 1 and 2 have an N-terminal signal sequence, followed by a threonine-rich region, a Short Consensus Repeat (SCR), a CUB-like domain, a second SCR, a second CUB-like domain, three tandem SCRs, a transmembrane domain, and a cytoplasmic C-terminal tail. They differ only in the region between the last SCR and the transmembrane domain. *SEZ6* was predicted to be involved in neuronal maturation and plasticity ([@B48]). Recently mutations and altered expression of this gene have been associated with Alzheimer's and Niemann-Pick disease ([@B19]; [@B53]).

The Tau TuBulin Kinase 2 (*TTBK2*) gene, located on 15q15.2, encodes a member of the casein kinase (CK1) group of eukaryotic protein kinases. *TTBK1* has been implicated in Alzheimer's disease (OMIM 104300) and in neurofibrillary tangles formation ([@B65]). Mutations in this gene also cause spinocerebellar ataxia 11 (SCA11; 604432). SCA11 is a pure progressive cerebellar ataxia that has been linked to 15q14-q21 ([@B81]; [@B37]). In an 8-generation English family they found a one-base insertion in the *TTBK2* gene creating a premature stop codon and a truncation of the normal protein (OMIM 611695.0001). In a second family of Pakistani ancestry, a different mutation was found (OMIM 611695.0002). Goetz et al. (2012) concluded that *TTBK2* is required for removal of CP110 for the initiation of ciliogenesis ([@B31]).

1.  3\) Candidate Genes From Cytogenetic Studies ([**Table 1**](#T1){ref-type="table"})

Interesting candidate genes deleted, duplicated, or truncated by the CNVs have also been found in cytogenetic studies (see above). These genes have brain expression and are mostly described in other neurodevelopmental or psychiatric disorders ([**Figure 1**](#f1){ref-type="fig"}). Nine genes are described as putative COS-causing genes: *CHRNA7* (15q13.3), *DGCR6* (22q11.2), *FMR1* (Xq27.3), *MYT1L* (2p25.3), *NRXN1* (2p16.3), *PRODH* (22q11.2), *PTK2* (8q24.3), *STS* (Xp22.31), and *SRGAP3* (3p25.3) ([@B82]; [@B50]; [@B75]; [@B44]; [@B71]; [@B76]; [@B26]; [@B79]; [@B1]; [@B55]; [@B80]; [@B43]; [@B6]; [@B25]; [@B85]; [@B47]).

Conclusions {#s4}
===========

COS is a neurodevelopmental disorder with several degrees of complexity (clinical and genetic heterogeneity). Clinically, getting the diagnostic is very challenging (severe disorder, comorbidities, and association with other neurodevelopmental disorders) ([@B30]). The clinical overlap with ASD is well documented and in our study we found a co-morbidity rate (33%) nearly equal to the National Institute of Mental Health (NIMH) COS cohort rate (28%) ([@B56]). The genetic overlap with ASD is also well documented and we show that 91% of described CNVs are also described in ASD (*SFARI*). In the literature, we found only 20% of COS patients with co-morbid ADHD vs. 84% according to Ross et al. and we hypothesize that this trouble was under-diagnosed in schizophrenia studies ([@B61]). All intellectual, motor, communication, and learning impairments are also frequently observed in COS ([@B61]; [@B50]). Psychiatric comorbidities were rarely described (two cases of mood disorders and two cases of anxiety disorders), which was an unexpected outcome given the published literature ([@B61]). Here, we highlight that only one-third of the full phenotypes associated with the mutations published in the literature are described, which constitutes a significant loss of information for researchers. Therefore, it appears fundamental to carry out preliminary work before genetic testing: perform a rigorous and homogeneous phenotypic characterization using International Classification of Disease (*ICD-10* and *DSM-5*) with standardized and internationally validated psychiatric categorical assessments and in accordance with medical history (including perinatology), biography (with significant life event and trauma), and environmental factors (such as toxic exposure).

COS is characterized by a complex genetic architecture with both inherited and *de novo* mutations distributed in almost all chromosomes. Most of the genes causing COS are unknown yet. It is interesting that, the few that have been already proposed (see before) are involved both in neurodevelopmental and neurodegenerative disorders such as Parkinson, Alzheimer, or ataxia. Moreover, schizophrenia has been shown to have complex genetic traits with high polygenic risk ([@B7]). Thus, a second hit (or more), in addition to CNV, is probably essential to explain the phenotypes. It includes *de novo* SNVs, other CNVs and/or environmental factors (e.g., trauma at early childhood, central nervous system infections or injuries) ([@B23]). At the interplay between genetic and environmental factors, epigenetics opens new perspectives to understand biological mechanisms of psychosis. In fact, recent findings suggest that pangenomic methylation changes during adolescence accompany conversion to psychosis ([@B41]). In clinical practice, as suggested by Szego et al. for ASD ([@B74]), it would seem useful to propose to COS patients genetic sequencing instead or in addition to microarrays ([@B11]; [@B69]) to improve genetic testing and to allow *de novo* SNV detection.

In research, the major challenge of the upcoming years will be the analysis of big data from NGS (prioritization and interpretation of DNA variations) ([@B59]) and the experimental validation of putative mutations. Sharing data with other teams around the world will be helpful to unravel the molecular pathology of COS and its underlying causes, paving the way for an early therapeutic intervention.
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